Spero Therapeutics Inc (SPRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Spero Therapeutics Inc (SPRO) has a cash flow conversion efficiency ratio of -0.141x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.35 Million) by net assets ($59.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Spero Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Spero Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Spero Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Spero Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Spero Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nakamoto Inc.
NASDAQ:NAKA
|
-0.015x |
|
I Controls Inc
KO:039570
|
0.032x |
|
Grammer AG
XETRA:GMM
|
-0.141x |
|
Moller Y Perez
SN:MOLLER
|
-0.016x |
|
The Andhra Sugars Limited
NSE:ANDHRSUGAR
|
0.065x |
|
Epileds Technologies Inc
TW:4956
|
0.021x |
|
Adriano Care SOCIMI SAU
MC:YADR
|
0.009x |
|
Freelance.Com
PA:ALFRE
|
0.021x |
Annual Cash Flow Conversion Efficiency for Spero Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Spero Therapeutics Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Spero Therapeutics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $59.02 Million | $-12.62 Million | -0.214x | +57.92% |
| 2024-12-31 | $46.12 Million | $-23.44 Million | -0.508x | -64.67% |
| 2023-12-31 | $106.89 Million | $-32.99 Million | -0.309x | -203.18% |
| 2022-12-31 | $75.93 Million | $-7.73 Million | -0.102x | +86.03% |
| 2021-12-31 | $88.29 Million | $-64.35 Million | -0.729x | -12.07% |
| 2020-12-31 | $132.04 Million | $-85.87 Million | -0.650x | +3.04% |
| 2019-12-31 | $74.57 Million | $-50.02 Million | -0.671x | -96.11% |
| 2018-12-31 | $115.86 Million | $-39.62 Million | -0.342x | +25.71% |
| 2017-12-31 | $84.96 Million | $-39.11 Million | -0.460x | +89.89% |
| 2016-12-31 | $6.36 Million | $-28.96 Million | -4.553x | -112.18% |
| 2015-12-31 | $-257.00K | $-9.61 Million | 37.385x | -- |
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including … Read more